Ratiani, L.; Pachkoria, E.; Mamageishvili, N.; Shengelia, R.; Hovhannisyan, A.; Panossian, A.
Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals 2022, 15, 1013.
https://doi.org/10.3390/ph15081013
AMA Style
Ratiani L, Pachkoria E, Mamageishvili N, Shengelia R, Hovhannisyan A, Panossian A.
Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals. 2022; 15(8):1013.
https://doi.org/10.3390/ph15081013
Chicago/Turabian Style
Ratiani, Levan, Elene Pachkoria, Nato Mamageishvili, Ramaz Shengelia, Areg Hovhannisyan, and Alexander Panossian.
2022. "Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial" Pharmaceuticals 15, no. 8: 1013.
https://doi.org/10.3390/ph15081013
APA Style
Ratiani, L., Pachkoria, E., Mamageishvili, N., Shengelia, R., Hovhannisyan, A., & Panossian, A.
(2022). Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals, 15(8), 1013.
https://doi.org/10.3390/ph15081013